U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H38N2O2
Molecular Weight 458.6349
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELACESTRANT

SMILES

[H][C@]1(CCC2=CC(O)=CC=C2C1)C3=C(C=C(OC)C=C3)N(CC)CC4=CC=C(CCNCC)C=C4

InChI

InChIKey=SIFNOOUKXBRGGB-AREMUKBSSA-N
InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1

HIDE SMILES / InChI
Molecular Formula C30H38N2O2
Molecular Weight 458.6349
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Elacestrant (ER-306323 or RAD 1901 [6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride]) is a selective estrogen receptor (ER) degrader. Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth in breast cancer xenograft models. Elacestrant has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Elacestrant is being developed by Radius Health, for the treatment of estrogen receptor positive breast cancer.

Originator

Approval Year

2023
455
Targets

Targets

Primary TargetPharmacologyConditionPotency
Estrogen receptor
75
Target ID: P03372
Gene ID: 2099.0
Gene Symbol: ESR1
Target Organism: Homo sapiens (Human)
Modulator
828
PubMed

PubMed

TitleDatePubMed
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER(+) Breast Cancer Patient-derived Xenograft Models.
2017 Aug 15

Sample Use Guides

In Vivo Use Guide
400 mg/day once daily
Route of Administration: Oral
In Vitro Use Guide
Elacestrant treatment also inhibited E2-mediated proliferation in MCF7 and T47D cells in a dose-dependent manner
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:42:51 GMT 2023
Edited
by admin
on Sat Dec 16 09:42:51 GMT 2023
Record UNII
FM6A2627A8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELACESTRANT
INN   WHO-DD  
INN   USAN  
Official Name English
RAD1901
Code English
ER-306323
Code English
RAD-1901
Code English
(2R)-2-(2-(ETHYL-((4-(2-(ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXY-PHENYL)TETRALIN-6-OL
Systematic Name English
elacestrant [INN]
Common Name English
2-NAPHTHALENOL, 6-(2-(ETHYL((4-(2-(ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXYPHENYL)-5,6,7,8-TETRAHYDRO-, (6R)-
Systematic Name English
ELACESTRANT [USAN]
Common Name English
Elacestrant [WHO-DD]
Common Name English
(6R)-6-(2-(ETHYL((4-(2- (ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXYPHENYL)- 5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1821
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
Code System Code Type Description
USAN
GH-120
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
RAD-1901
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
NCI_THESAURUS
C120211
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
RAD-1901
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY Description: RAD1901 is an orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of RAD1901, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, RAD1901 is able to cross the blood-brain barrier (BBB). (last updated: 5/19/2016).Synonym: RAD1901, RAD-1901, RAD 1901, RAD1901 HCl salt.
ChEMBL
CHEMBL3545015
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
SMS_ID
100000170507
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
EVMPD
SUB184531
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
CAS
722533-56-4
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID901045846
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
DAILYMED
FM6A2627A8
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
DRUG BANK
DB06374
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
FDA UNII
FM6A2627A8
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
PUBCHEM
23642301
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
WIKIPEDIA
Elacestrant
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
INN
10247
Created by admin on Sat Dec 16 09:42:51 GMT 2023 , Edited by admin on Sat Dec 16 09:42:51 GMT 2023
PRIMARY
Related Record Type Details
ESTROGEN RECEPTOR
TARGET->INHIBITOR, RECEPTOR DEGRADER
Structure of ELACESTRANT HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ELACESTRANT
ACTIVE MOIETY
Class: Osteoporosis therapy, Small molecule, Tetra-hydro-naphthalene; Mechanism of Action: Selective estrogen receptor degraders, Selective estrogen receptor modulator; Highest Development Phases: Phase II for Vasomotor symptoms, Phase I for Breast cancer; Most Recent Events: 08 Feb 2016 Radius, in collaboration with Novartis, plan a clinical trial for RAD 1901 in combination with LEE 011 in the treatment of Breast cancer, 27 Jan 2016 Radius Health and Novartis enter into a clinical collaboration to evaluate combination regimens, RAD 1901 and ricociclib, for the treatment of Breast cancer, 01 Dec 2015 Phase-II clinical trials in Vasomotor symptoms in USA (PO) (NCT02653417)
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966